DK2382331T3 - Cancerbiomarkører - Google Patents

Cancerbiomarkører Download PDF

Info

Publication number
DK2382331T3
DK2382331T3 DK10729525.5T DK10729525T DK2382331T3 DK 2382331 T3 DK2382331 T3 DK 2382331T3 DK 10729525 T DK10729525 T DK 10729525T DK 2382331 T3 DK2382331 T3 DK 2382331T3
Authority
DK
Denmark
Prior art keywords
patient
genes
expression
recurrence
determining
Prior art date
Application number
DK10729525.5T
Other languages
English (en)
Inventor
Steve Stone
Alexander Gutin
Susanne Wagner
Julia Reid
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Application granted granted Critical
Publication of DK2382331T3 publication Critical patent/DK2382331T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (9)

1. Fremgangsmåde til klassificering af prostatacancer omfattende bestemmelse af ekspressionsniveauet af et panel af gener omfattende alle celle-cyklusgener anført i et hvilket som helst af paneler C til G, hvor forøget ekspression af cellecyklusgenerne indikerer en dårlig prognose.
2. Fremgangsmåde til klassificering af prostatacancer omfatter bestemmelse af mindst en klinisk parameter for en cancerpatient og bestemmelse af ekspressionsniveauet af alle celle-cyklusgener anført i et hvilket som helst af panelerne C til G i en prøve opnået fra patienten, hvor et gentagelse-associeret klinisk parameter eller forøget ekspression af celle-cyklusgenerne indikerer en dårlig prognose.
3. Fremgangsmåden ifølge krav 2 yderligere omfattende bestemmelse af to eller flere kliniske parametre, hvor de to eller flere kliniske parametre danner eller er del af et nomogram omfattende enten de kliniske parametre af Kattan-Stephenson-nomogrammet eller de kliniske parametre af Nottingham Prognostic Indexet.
4. Fremgangsmåden ifølge krav 1 yderligere omfattende bestemmelse af ekspressionsniveauet af PTEN i en prøve opnået fra patienten, hvor negativ eller lav PTEN status indikerer en dårlig prognose.
5. Fremgangsmåden ifølge krav 2 yderligere omfattende bestemmelse af ekspressionsniveauet af PTEN i en prøve opnået fra patienten, hvor negativ eller lav PTEN status indikerer en dårlig prognose.
6. Fremgangsmåde til bestemmelse af et behandlingsforløb for en prostatacancerpatient omfattende bestemmelse af ekspressionsniveauet af et panel af gener omfattende alle celle-cyklusgener anført i et hvilket som helst af panelerne C til G i en prøve opnået fra patienten, og (a) anbefaling, ordinering eller initiering aktiv behandling hvis prøven har forøget ekspression af cellecyklusgenerne, eller (b) anbefaling, ordinering eller initiering årvågen afventning hvis prøven ikke har forøget ekspression af cellecyklusgenerne.
7. Fremgangsmåde til bestemmelse hvorvidt en prostacancerpatient har en forøget sandsynlighed af tilbagevenden omfattende: (a) bestemme ekspressionsniveauet af et panel af gener omfattende alle celle-cyklusgener anført i et hvilket som helst af panelerne C til G i en prøve fra en patient; (b) bedømme informationen opnået i (a) i et computer-læsbart medium; (c) spørge om denne information for at bestemme hvorvidt en prøve opnået fra patienten viser forøget ekspression af cellecyklusgenerne; og (d) udlæse en indikation at patienten har en forøget sandsynlighed af tilbagevenden hvis prøven viser forøget ekspression af cellecyklusgenerne.
8. Kit omfattende en flerhed af oligonukleotider til bestemmelse af ekspressionsniveauet af et panel af gener, hvor panelet omfatter alle gener i et hvilket som helst af paneler C til G og hvor kittet består af reagenser til bestemmelse af ekspressionen af ikke mere end 2500 gener.
9. Anvendelse afen flerhed af oligonukleotider til bestemmelse af ekspressionsniveauet af et panel af gener, hvor panelet omfatter alle gener anført i et hvilket som helst af paneler C til G for at bestemme prognosen eller sandsynligheden for tilbagevenden af prostatacancer i en prøve opnået fra en patient.
DK10729525.5T 2009-01-07 2010-01-07 Cancerbiomarkører DK2382331T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14307709P 2009-01-07 2009-01-07
US17965009P 2009-05-19 2009-05-19
US18590109P 2009-06-10 2009-06-10
US24174809P 2009-09-11 2009-09-11
US25644309P 2009-10-30 2009-10-30
PCT/US2010/020397 WO2010080933A1 (en) 2009-01-07 2010-01-07 Cancer biomarkers

Publications (1)

Publication Number Publication Date
DK2382331T3 true DK2382331T3 (da) 2016-08-22

Family

ID=42316814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10729525.5T DK2382331T3 (da) 2009-01-07 2010-01-07 Cancerbiomarkører

Country Status (11)

Country Link
EP (4) EP3118328A1 (da)
JP (1) JP2012514474A (da)
KR (1) KR20110111462A (da)
CN (1) CN102482711A (da)
AU (4) AU2010203542B2 (da)
BR (1) BRPI1006075A2 (da)
CA (1) CA2749103A1 (da)
DK (1) DK2382331T3 (da)
ES (1) ES2595410T3 (da)
NZ (1) NZ594003A (da)
WO (1) WO2010080933A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
WO2012006447A2 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
ES2611000T3 (es) 2010-07-27 2017-05-04 Genomic Health, Inc. Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
WO2012135008A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
WO2012168421A1 (en) 2011-06-10 2012-12-13 Deutsches Krebsforschungszentrum Prediction of recurrence for bladder cancer by a protein signature in tissue samples
EP2744919A4 (en) * 2011-08-19 2015-04-08 Myriad Genetics Inc GENE SIGNATURES FOR PROGNOSIS OF LUNG CANCER AND SELECTION OF THERAPY
WO2013112528A1 (en) * 2012-01-23 2013-08-01 West Chester University Of Pennsylvania Methods and compositions relating to proliferative disorders of the prostate
EP3179393B1 (en) 2012-01-31 2020-07-08 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
US10106854B2 (en) 2012-06-14 2018-10-23 Aarhus Universitet Biomarkers for prostate cancer
WO2014078700A1 (en) * 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101432172B1 (ko) * 2013-01-22 2014-08-22 한국원자력의학원 Ｍｒｆａｐ1을 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도
JP2016515800A (ja) * 2013-02-21 2016-06-02 ミリアド・ジェネティックス・インコーポレイテッド 肺癌の予後および治療選択のための遺伝子サイン
WO2014160120A1 (en) * 2013-03-14 2014-10-02 Neogenomics Laboratories, Inc. Compositions and methods for detecting and determining a prognosis for prostate cancer
CN105518151B (zh) * 2013-03-15 2021-05-25 莱兰斯坦福初级大学评议会 循环核酸肿瘤标志物的鉴别和用途
EP4043580A1 (en) 2013-03-15 2022-08-17 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
CA2930972A1 (en) * 2013-12-04 2015-06-11 Myriad Genetics, Inc. Gene signatures for renal cancer prognosis
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
AU2015284460B2 (en) 2014-07-02 2021-10-07 Myriad Mypath, Llc Genes and gene signatures for diagnosis and treatment of melanoma
EP3400312A4 (en) 2016-01-06 2019-08-28 Myriad Genetics, Inc. GENES AND GENETIC SIGNATURES FOR THE DIAGNOSIS AND TREATMENT OF MELANOMA
KR101886493B1 (ko) * 2016-04-29 2018-08-07 연세대학교 산학협력단 구강암 발병 확률 예측 방법 및 장치
WO2017193062A1 (en) 2016-05-06 2017-11-09 Myriad Genetics, Inc. Gene signatures for renal cancer prognosis
CN105893782A (zh) * 2016-05-26 2016-08-24 江苏省人民医院 前列腺癌风险预测装置
WO2018214249A1 (zh) * 2017-05-22 2018-11-29 立森印迹诊断技术（无锡）有限公司 一种印记基因分级模型及其组成的系统和应用
CN108504555B (zh) * 2018-04-16 2021-08-03 图灵人工智能研究院（南京）有限公司 鉴别及评价肿瘤进展的装置和方法
CN112941184A (zh) * 2018-06-13 2021-06-11 深圳市颐康生物科技有限公司 一种用于检测癌症复发风险的生物标志物
KR102184992B1 (ko) * 2018-10-19 2020-12-01 연세대학교 산학협력단 유방암 환자에서 수술 중 겨드랑이 림프절 전이 진단을 위한 디바이스
WO2020226333A1 (ko) * 2019-05-03 2020-11-12 주식회사 디시젠 암 예후 예측방법 및 이의 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
DE69823206T2 (de) 1997-07-25 2004-08-19 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Verfahren zur herstellung einer bio-informatik-datenbank
US6420108B2 (en) 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
WO1999009218A1 (en) 1997-08-15 1999-02-25 Affymetrix, Inc. Polymorphism detection utilizing clustering analysis
US6185561B1 (en) 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
US20030097222A1 (en) 2000-01-25 2003-05-22 Craford David M. Method, system, and computer software for providing a genomic web portal
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20020183936A1 (en) 2001-01-24 2002-12-05 Affymetrix, Inc. Method, system, and computer software for providing a genomic web portal
US20030120432A1 (en) 2001-01-29 2003-06-26 Affymetrix, Inc. Method, system and computer software for online ordering of custom probe arrays
US20030100995A1 (en) 2001-07-16 2003-05-29 Affymetrix, Inc. Method, system and computer software for variant information via a web portal
US20030235816A1 (en) * 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20040049354A1 (en) 2002-04-26 2004-03-11 Affymetrix, Inc. Method, system and computer software providing a genomic web portal for functional analysis of alternative splice variants
EP3470535B1 (en) * 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
US20070026424A1 (en) * 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
EP1880335A1 (en) * 2005-05-13 2008-01-23 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
EP2754720A1 (en) * 2007-02-23 2014-07-16 Aviaradx, Inc. Prostate cancer survival and recurrence
CA2688477C (en) * 2007-06-01 2020-12-22 The Regents Of The University Of California Multigene prognostic assay for lung cancer

Also Published As

Publication number Publication date
AU2019210509A1 (en) 2019-08-15
EP2382331B1 (en) 2016-06-08
AU2010203542A1 (en) 2011-07-28
ES2595410T3 (es) 2016-12-29
EP2382331A1 (en) 2011-11-02
CA2749103A1 (en) 2010-07-15
AU2019210509B2 (en) 2022-03-10
EP3524697A1 (en) 2019-08-14
AU2010203542B2 (en) 2017-02-23
WO2010080933A1 (en) 2010-07-15
CN102482711A (zh) 2012-05-30
EP4328589A2 (en) 2024-02-28
AU2022200945A1 (en) 2022-03-03
EP2382331A4 (en) 2013-01-16
EP3118328A1 (en) 2017-01-18
AU2017203453A1 (en) 2017-06-08
JP2012514474A (ja) 2012-06-28
KR20110111462A (ko) 2011-10-11
NZ594003A (en) 2012-11-30
BRPI1006075A2 (pt) 2016-04-19

Similar Documents

Publication Publication Date Title
DK2382331T3 (da) Cancerbiomarkører
US8349555B2 (en) Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
JP5020088B2 (ja) 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
JP2020031642A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
ES2938766T3 (es) Firmas génicas para el pronóstico de cáncer
JP2009528825A (ja) デュークスｂ大腸がんの再発を予測するための分子的解析
EP2121988B1 (en) Prostate cancer survival and recurrence
JP2015057055A (ja) 腫瘍グレード分類と癌の予後診断
WO2009137921A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20140134166A1 (en) Hypoxia-related gene signatures for cancer classification
WO2012066451A1 (en) Prognostic and predictive gene signature for colon cancer
JP2011509689A (ja) Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断
WO2012016332A1 (en) Prognostic gene signatures for non-small cell lung cancer
WO2013028554A2 (en) Gene signatures for lung cancer prognosis and therapy selection
JP2016515800A (ja) 肺癌の予後および治療選択のための遺伝子サイン
WO2016118670A1 (en) Multigene expression assay for patient stratification in resected colorectal liver metastases
EP2582848A2 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20180051342A1 (en) Prostate cancer survival and recurrence
WO2013079188A1 (en) Methods for the diagnosis, the determination of the grade of a solid tumor and the prognosis of a subject suffering from cancer
US20140212415A1 (en) Hypoxia-related gene signatures for cancer classification
WO2017193062A1 (en) Gene signatures for renal cancer prognosis
JP2023531572A (ja) 前立腺癌の分子分類器
US20160281177A1 (en) Gene signatures for renal cancer prognosis